Ryo Tamamura
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ryo Tamamura has a total of 101 co-authors. Here are the top co-authors by number of shared publications:
Hitoshi Nagatsuka
Department of Oral Pathology and Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan
18 shared publicationsNoriyuki Nagai
7 shared publicationsEsra Gunduz
6 shared publicationsHidetsugu Tsujigiwa
Department of Oral Pathology and Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, nagano, Japan
6 shared publicationsMehmet Gunduz
6 shared publications- Naoki Katase
Department of Oral Pathology, Graduate School of Biomedical Sciences, Nagasaki University, Sakamoto 1-7-1, Nagasaki, Nagasaki, 852-8588, Japan
6 shared publications
Latest Publications
- 22 December 2012
- Published by Springer Nature in Calcified Tissue International
- Vol. 92 (3) , 296-306
The Role of Bone Marrow-Derived Cells During the Bone Healing Process in the GFP Mouse Bone Marrow Transplantation Model
Bone healing is a complex and multistep process in which the origin of the cells participating in bone repair is still unknown. The involvement of bone marrow-derived cells in tissue repair has been the subject of recent studies. In the present study, bone marrow-derived cells in bone healing were traced using the GFP bone marrow transplantation model. Bone marrow cells from C57BL/6-Tg (CAG-EGFP) were transplanted into C57BL/6 J wild mice. After transplantation, bone injury was created using a 1.0-mm drill. Bone healing was histologically assessed at 3, 7, 14, and 28 postoperative days. Immunohistochemistry for GFP; double-fluorescent immunohistochemistry for GFP-F4/80, GFP-CD34, and GFP-osteocalcin; and double-staining for GFP and tartrate-resistant acid phosphatase were performed. Bone marrow transplantation successfully replaced the hematopoietic cells into GFP-positive donor cells. Immunohistochemical analyses revealed that osteoblasts or osteocytes in the repair stage were GFP-negative, whereas osteoclasts in the repair and remodeling stages and hematopoietic cells were GFP-positive. The results indicated that bone marrow-derived cells might not differentiate into osteoblasts. The role of bone marrow-derived cells might be limited to adjustment of the microenvironment by differentiating into inflammatory cells, osteoclasts, or endothelial cells in immature blood vessels.
- 22 December 2012
- Published by Springer Nature in Calcified Tissue International
- Vol. 92 (3) , 296-306
The Role of Bone Marrow-Derived Cells During the Bone Healing Process in the GFP Mouse Bone Marrow Transplantation Model
Bone healing is a complex and multistep process in which the origin of the cells participating in bone repair is still unknown. The involvement of bone marrow-derived cells in tissue repair has been the subject of recent studies. In the present study, bone marrow-derived cells in bone healing were traced using the GFP bone marrow transplantation model. Bone marrow cells from C57BL/6-Tg (CAG-EGFP) were transplanted into C57BL/6 J wild mice. After transplantation, bone injury was created using a 1.0-mm drill. Bone healing was histologically assessed at 3, 7, 14, and 28 postoperative days. Immunohistochemistry for GFP; double-fluorescent immunohistochemistry for GFP-F4/80, GFP-CD34, and GFP-osteocalcin; and double-staining for GFP and tartrate-resistant acid phosphatase were performed. Bone marrow transplantation successfully replaced the hematopoietic cells into GFP-positive donor cells. Immunohistochemical analyses revealed that osteoblasts or osteocytes in the repair stage were GFP-negative, whereas osteoclasts in the repair and remodeling stages and hematopoietic cells were GFP-positive. The results indicated that bone marrow-derived cells might not differentiate into osteoblasts. The role of bone marrow-derived cells might be limited to adjustment of the microenvironment by differentiating into inflammatory cells, osteoclasts, or endothelial cells in immature blood vessels.
- Open Access
- 1 January 2011
- Published by Society for Hard Tissue Regenerative Biology in Journal of Hard Tissue Biology
- Vol. 20 (4) , 301-306
Transplanted Bone Marrow-derived Cell Migration into Periodontal Tissues and Cell Differentiation
- 1 January 2011
- Published by Society for Hard Tissue Regenerative Biology in Journal of Hard Tissue Biology
- Vol. 20 (4) , 301-306
Open AccessTransplanted Bone Marrow-derived Cell Migration into Periodontal Tissues and Cell Differentiation
- 1 January 2011
- Published by Society for Hard Tissue Regenerative Biology in Journal of Hard Tissue Biology
- Vol. 20 (2) , 115-124
Molecular Screening of Anti-quorum Sensing Capability of Salvadora Persica on Enterococcus Faecalis
- 1 January 2011
- Published by Society for Hard Tissue Regenerative Biology in Journal of Hard Tissue Biology
- Vol. 20 (2) , 115-124
Molecular Screening of Anti-quorum Sensing Capability of Salvadora Persica on Enterococcus Faecalis
- 16 December 2009
- Published by Taylor & Francis in Cancer Investigation
- Vol. 28 (5) , 495-500
Expression and Mutation Analysis of Her2 in Head and Neck Squamous Cell Carcinoma
We analyzed mutation and expression status of human epidermal growth factor receptor 2 (Her2) in head and neck squamous cell carcinoma (HNSCC) using single strand conformation polymorphism (SSCP) mutation analysis and immunohistochemistry (IHC). Mutations were absent in all 85 cases. Out of 57 cases available for IHC, Her2 protein expression was negative (0) in 40 tumors (70%). Seventeen tumors (29.8%) expressed Her2, among these 13 tumors (22.8%) showed a weak (+1) expression and 4 (7%) showed a moderate expression (+2), none showed a strong (+3) expression. There was not a significant association between expression and any of the patients’ clinical variables or prognosis. Our results suggest that Her2 may not be useful as a molecular target in HNSCC.
- 16 December 2009
- Published by Taylor & Francis in Cancer Investigation
- Vol. 28 (5) , 495-500
Expression and Mutation Analysis of Her2 in Head and Neck Squamous Cell Carcinoma
We analyzed mutation and expression status of human epidermal growth factor receptor 2 (Her2) in head and neck squamous cell carcinoma (HNSCC) using single strand conformation polymorphism (SSCP) mutation analysis and immunohistochemistry (IHC). Mutations were absent in all 85 cases. Out of 57 cases available for IHC, Her2 protein expression was negative (0) in 40 tumors (70%). Seventeen tumors (29.8%) expressed Her2, among these 13 tumors (22.8%) showed a weak (+1) expression and 4 (7%) showed a moderate expression (+2), none showed a strong (+3) expression. There was not a significant association between expression and any of the patients’ clinical variables or prognosis. Our results suggest that Her2 may not be useful as a molecular target in HNSCC.
- 8 December 2009
- Published by Taylor & Francis in Cancer Investigation
- Vol. 28 (1) , 103-110
Frequent Allelic Loss of Dkk-1 Locus (10q11.2) is Related with Low Distant Metastasis and Better Prognosis in Head and Neck Squamous Cell Carcinomas
Head and neck squamous cell carcinoma (HNSCC) is a frequently occurring cancer worldwide. Dickkopf (Dkk)-1 gene is suggested to function as tumor suppressor gene (TSG) in several kinds of malignancies. In this study, we performed loss of heterozygosity (LOH) analysis of Dkk-1 and examined the correlation between LOH status and clinicopathological parameters for the first time. A pretty high LOH ratio (50%) was detected. Interestingly, in the cases with Dkk-1 retention group showed less distant metastasis and a tendency of longer disease free survival. These results indicate that Dkk-1 can play a role in HNSCC carcinogenesis and it may also be related to distant metastasis.
- 8 December 2009
- Published by Taylor & Francis in Cancer Investigation
- Vol. 28 (1) , 103-110
Frequent Allelic Loss of Dkk-1 Locus (10q11.2) is Related with Low Distant Metastasis and Better Prognosis in Head and Neck Squamous Cell Carcinomas
Head and neck squamous cell carcinoma (HNSCC) is a frequently occurring cancer worldwide. Dickkopf (Dkk)-1 gene is suggested to function as tumor suppressor gene (TSG) in several kinds of malignancies. In this study, we performed loss of heterozygosity (LOH) analysis of Dkk-1 and examined the correlation between LOH status and clinicopathological parameters for the first time. A pretty high LOH ratio (50%) was detected. Interestingly, in the cases with Dkk-1 retention group showed less distant metastasis and a tendency of longer disease free survival. These results indicate that Dkk-1 can play a role in HNSCC carcinogenesis and it may also be related to distant metastasis.
- 1 October 2009
- Published by Tech Science Press in Oncology Research
- Vol. 18 (10) , 509-518
Allelic Loss of the ING Gene Family Loci Is a Frequent Event in Ameloblastoma
Ameloblastoma is the most frequently encountered odontogenic tumor, characterized by a locally invasive behavior, frequent recurrences, and, although rare, metastatic capacity. Loss or inactivation of tumor suppressor genes (TSGs) allows cells to acquire neoplastic growth. The ING family proteins are tumor suppressors that physically and functionally interact with p53 to perform important roles in apoptosis, DNA repair, cell cycle regulation, and senescence. TP53 genetic alterations were reported to infrequently occur in ameloblastoma. Considering that other TSGs related to TP53 could be altered in this tumor, we focused our study on the ING family genes. We analyzed the loss of heterozygosity (LOH) status of the ING family (ING1‐ING5) chromosomal loci in a group of ameloblastomas by microsatellite analysis, and correlated the ING LOH status with clinicopathological characteristics. By using specific microsatellite markers, high frequency of LOH was found at the loci of each ING gene family member (33.3‐72.2%). A significant relationship was shown between LOH of D2S140 (ING5 locus) and solid tumor type (p = 0.02). LOH of ING3MS (ING3 locus) was also high in solid type tumors, showing a near significant association. In addition, a notable tendency toward higher LOH for half of the markers was observed in recurrent cases. LOH of ING family genes appears as a common genetic alteration in solid ameloblastoma. The current study provides interesting novel information regarding the potential prognostic significance of the allelic loss of the ING gene family loci in ameloblastoma tumorigenesis.
- 1 October 2009
- Published by Tech Science Press in Oncology Research
- Vol. 18 (10) , 509-518
Allelic Loss of the ING Gene Family Loci Is a Frequent Event in Ameloblastoma
Ameloblastoma is the most frequently encountered odontogenic tumor, characterized by a locally invasive behavior, frequent recurrences, and, although rare, metastatic capacity. Loss or inactivation of tumor suppressor genes (TSGs) allows cells to acquire neoplastic growth. The ING family proteins are tumor suppressors that physically and functionally interact with p53 to perform important roles in apoptosis, DNA repair, cell cycle regulation, and senescence. TP53 genetic alterations were reported to infrequently occur in ameloblastoma. Considering that other TSGs related to TP53 could be altered in this tumor, we focused our study on the ING family genes. We analyzed the loss of heterozygosity (LOH) status of the ING family (ING1‐ING5) chromosomal loci in a group of ameloblastomas by microsatellite analysis, and correlated the ING LOH status with clinicopathological characteristics. By using specific microsatellite markers, high frequency of LOH was found at the loci of each ING gene family member (33.3‐72.2%). A significant relationship was shown between LOH of D2S140 (ING5 locus) and solid tumor type (p = 0.02). LOH of ING3MS (ING3 locus) was also high in solid type tumors, showing a near significant association. In addition, a notable tendency toward higher LOH for half of the markers was observed in recurrent cases. LOH of ING family genes appears as a common genetic alteration in solid ameloblastoma. The current study provides interesting novel information regarding the potential prognostic significance of the allelic loss of the ING gene family loci in ameloblastoma tumorigenesis.
- 1 October 2009
- Published by Elsevier in Oral Oncology
- Vol. 45 (10) , 856-860
Secreted frizzled related protein (sFRP)-2 inhibits bone formation and promotes cell proliferation in ameloblastoma
- 1 October 2009
- Published by Elsevier in Oral Oncology
- Vol. 45 (10) , 856-860
Secreted frizzled related protein (sFRP)-2 inhibits bone formation and promotes cell proliferation in ameloblastoma
- 1 May 2009
- Published by Bentham Science Publishers Ltd. in Current Drug Targets
- Vol. 10 (5) , 465-476
Potential Usage of ING Family Members in Cancer Diagnostics and Molecular Therapy
Abstract: The Inhibitor of Growth (ING) gene family is an emerging putative type II tumor suppressor gene (TSG). Proteins of INGs (ING1-5), critical modulator of the histone code via PHD fingers, are able to suppress cell growth and proliferation, induce apoptosis, and modulate cell cycle progression. ING proteins are involved in transcriptional regulation of genes, such as the p53-inducible gene p21. ING proteins also serve as shuttling proteins between nucleus and cytoplasm, and dysregulation of this nucleocytoplasmic traffic has been shown in some cancer cells. In cancer cells, ING mRNA levels are often lost or suppressed but the genes are rarely mutated. Recently the potential roles of ING proteins as prognostic biomarkers, detection of aggressive behavior of the tumor as well as prediction of chemo-radiotherapy response have also emerged. In this review, we summarize the up-to-date knowledge on functions of the ING proteins, the protein status in human tumors and discuss as a potential target in the molecular diagnostics and therapy of cancer.
- 1 May 2009
- Published by Bentham Science Publishers Ltd. in Current Drug Targets
- Vol. 10 (5) , 465-476
Potential Usage of ING Family Members in Cancer Diagnostics and Molecular Therapy
Abstract: The Inhibitor of Growth (ING) gene family is an emerging putative type II tumor suppressor gene (TSG). Proteins of INGs (ING1-5), critical modulator of the histone code via PHD fingers, are able to suppress cell growth and proliferation, induce apoptosis, and modulate cell cycle progression. ING proteins are involved in transcriptional regulation of genes, such as the p53-inducible gene p21. ING proteins also serve as shuttling proteins between nucleus and cytoplasm, and dysregulation of this nucleocytoplasmic traffic has been shown in some cancer cells. In cancer cells, ING mRNA levels are often lost or suppressed but the genes are rarely mutated. Recently the potential roles of ING proteins as prognostic biomarkers, detection of aggressive behavior of the tumor as well as prediction of chemo-radiotherapy response have also emerged. In this review, we summarize the up-to-date knowledge on functions of the ING proteins, the protein status in human tumors and discuss as a potential target in the molecular diagnostics and therapy of cancer.
- 1 January 2009
- Published by Taylor & Francis in Cancer Investigation
- Vol. 27 (6) , 661-668
Loss of Heterozygosity at the 9p21–24 Region and Identification of BRM as a Candidate Tumor Suppressor Gene in Head and Neck Squamous Cell Carcinoma
We have analyzed allelic loss of the short arm of chromosome 9 in 39 head and neck cancers using 13 polymorphic markers and found two deletions of hot spots at 9p21 and 9p24. Loss of heterozygosity was detected at least at one locus in 28 of 39 cases (71.8%). P16, a well-known tumor suppressor gene, is considered to be a target for deletion of the 9p21 region. However, novel frequent chromosomal deletion and a candidate tumor suppressor gene, BRM at the 9p24 region, were detected. Moreover, comparison of clinicopathological variables demonstrated that loss of heterozygosity at the BRM locus was associated with a worse prognosis.
- 1 January 2009
- Published by Taylor & Francis in Cancer Investigation
- Vol. 27 (6) , 661-668
Loss of Heterozygosity at the 9p21–24 Region and Identification of BRM as a Candidate Tumor Suppressor Gene in Head and Neck Squamous Cell Carcinoma
We have analyzed allelic loss of the short arm of chromosome 9 in 39 head and neck cancers using 13 polymorphic markers and found two deletions of hot spots at 9p21 and 9p24. Loss of heterozygosity was detected at least at one locus in 28 of 39 cases (71.8%). P16, a well-known tumor suppressor gene, is considered to be a target for deletion of the 9p21 region. However, novel frequent chromosomal deletion and a candidate tumor suppressor gene, BRM at the 9p24 region, were detected. Moreover, comparison of clinicopathological variables demonstrated that loss of heterozygosity at the BRM locus was associated with a worse prognosis.
- 1 January 2009
- Published by Society for Hard Tissue Regenerative Biology in Journal of Hard Tissue Biology
- Vol. 18 (1) , 19-26
Immunohistochemical Detection of Erythropoietin, Platelet-Derived Growth Factor and Their Receptors in Ameloblastomas
- 1 January 2009
- Published by Society for Hard Tissue Regenerative Biology in Journal of Hard Tissue Biology
- Vol. 18 (1) , 19-26
Immunohistochemical Detection of Erythropoietin, Platelet-Derived Growth Factor and Their Receptors in Ameloblastomas